Amicus Therapeutics Inc
NASDAQ:FOLD
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
9.04
14.52
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Amicus Therapeutics Inc
Amicus Therapeutics Inc
Cash from Financing Activities
Amicus Therapeutics Inc
Cash from Financing Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Amicus Therapeutics Inc
NASDAQ:FOLD
|
Cash from Financing Activities
$31.7m
|
CAGR 3-Years
-49%
|
CAGR 5-Years
-32%
|
CAGR 10-Years
-8%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Cash from Financing Activities
-$2.8B
|
CAGR 3-Years
45%
|
CAGR 5-Years
25%
|
CAGR 10-Years
1%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cash from Financing Activities
-$6.8B
|
CAGR 3-Years
0%
|
CAGR 5-Years
4%
|
CAGR 10-Years
-3%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Cash from Financing Activities
-$5.3B
|
CAGR 3-Years
0%
|
CAGR 5-Years
21%
|
CAGR 10-Years
N/A
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cash from Financing Activities
-$1.2B
|
CAGR 3-Years
1%
|
CAGR 5-Years
-55%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cash from Financing Activities
-$1.5B
|
CAGR 3-Years
-55%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Amicus Therapeutics Inc
Glance View
In the ever-evolving landscape of biotech, Amicus Therapeutics Inc. stands as a beacon of innovation, rooted deeply in the realm of rare and orphan diseases. Founded with the mission to harness advanced therapies for conditions with limited treatment options, the company has carved a niche in developing treatments that hinge on cutting-edge science. Specifically, Amicus focuses on creating next-generation therapies involving chaperone proteins and genetic medicines. These specialized therapies work by stabilizing and enhancing the function of faulty proteins that are hallmarks of many genetic disorders, thereby directly addressing the underlying causes of these conditions. Their portfolio, prominently featuring Galafold (migalastat) for Fabry disease, exemplifies their approach—leveraging precision medicine to cater to patients who have been underserved by traditional pharmaceutical models. Revenue generation for Amicus Therapeutics predominantly revolves around the commercialization of Galafold, which is approved in numerous global markets. Galafold offers a personalized approach, being targeted towards individuals with Fabry disease who possess amenable genetic mutations. This specificity not only underscores Amicus's commitment to precision therapeutics but also reinforces its competitive edge, as the treatment reduces the necessity for enzymatic replacement, a conventional route with broader systemic impacts. Beyond its current offerings, Amicus is strategically investing in its pipeline of gene therapies, aiming to provide breakthroughs in conditions like Pompe disease and other rare metabolic disorders. By enhancing existing therapies and fostering new breakthroughs, Amicus not only upholds its commitment to patient-centric solutions but also bolsters its financial sustainability through strategic innovation and market expansion.
See Also
What is Amicus Therapeutics Inc's Cash from Financing Activities?
Cash from Financing Activities
31.7m
USD
Based on the financial report for Sep 30, 2024, Amicus Therapeutics Inc's Cash from Financing Activities amounts to 31.7m USD.
What is Amicus Therapeutics Inc's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 10Y
-8%
Over the last year, the Cash from Financing Activities growth was -41%. The average annual Cash from Financing Activities growth rates for Amicus Therapeutics Inc have been -49% over the past three years , -32% over the past five years , and -8% over the past ten years .
You don't have any saved screeners yet
